Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  35.00 2.12% 1,683.60 1,689.20 1,689.60 1,693.20 1,641.00 1,641.00 9,175,512 16:35:05
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 17.9 84,467

Glaxosmithkline Share Discussion Threads

Showing 20951 to 20973 of 21425 messages
Chat Pages: Latest  845  844  843  842  841  840  839  838  837  836  835  834  Older
DateSubjectAuthorDiscuss
19/3/2020
08:02
Wow: GBP 1.0 = USD 1.15 Big boost to GSK, (also dividend safe for sure)
tradermichael
18/3/2020
18:22
It has been. I know it is down but is my best performer - crazy I know but a 4.3% reduction today almost feels good compared to othersAgree with zicopele on sterling
watfordhornet
18/3/2020
16:40
Depreciation of Stg will provide some support. Expecting fall in dividend.
zicopele
18/3/2020
14:21
would have expected GSK to be a bit more resilient to the market sell off
mister md
18/3/2020
13:08
Unlike India or Japan Big pharmas are not talking any chances which could backfire.
abdullla
18/3/2020
13:03
TM i think reading between the lines it answers my question,I hope the experts sort this mess out sooner than latter.
abdullla
18/3/2020
12:16
Some companies have cancelled their forthcoming dividend,is there any chance GSK could do the same ???
abdullla
17/3/2020
16:50
Over 22 million GSK shares traded today GBP 1.0 = USD 1.20, good for income
tradermichael
17/3/2020
12:40
Der US-Pharmakonzern Pfizer arbeitet mit der Mainzer Biotech-Firma BioNtech SE an der Entwicklung eines Coronavirus-Impfstoffs. They collaborated from 2018.
alphorn
17/3/2020
12:29
Regeneron reported that tests for its "antibody-based" remedies for the coronavirus infection could be ready for the final round of clinical testing by the beginning of the summer, which could see a drug shipped by the end of the summer, according to CNBC's Meg Tirrell. Pfizer, meanwhile, announced it would partner with a Swiss biotech company to produce a vaccine using a technology similar to Moderna. Reporting from Beijing, CNBC's Eunice Yoon, reported that a Chinese trial for favipiravir, another antiviral designed to treat the virus, showed "promising" results.
crossing_the_rubicon
17/3/2020
11:24
A potential COVID-19 vaccine from Moderna (NASDAQ:MRNA) has moved into human testing, with the first participant receiving treatment on Monday. A total of 45 healthy adults will receive one of three dose levels (25, 100, 250 µg) of the candidate, called mRNA-1273, and will be followed for 12 months after receiving the second vaccination. The primary endpoint is safety, including reactogenicity (the expected adverse events such as excessive immunological responses and injection site reactions). The secondary endpoint is immunogenicity (the robustness of the immune response).
crossing_the_rubicon
17/3/2020
08:18
GBP 1.00 = USD 1.22
tradermichael
17/3/2020
08:14
PramBigear - Exactly! …. ;0)
tradermichael
17/3/2020
07:56
Hi Monty - what news is the that?
bilster1
16/3/2020
21:15
Seen the article several newspapers, could be massive if it works for GSK.
montyhedge
16/3/2020
19:09
Health Canada has approved the use of GlaxoSmithKline's (GSK -9.6%) Nucala (mepolizumab) in children as young as six years old with severe eosinophilic asthma. The previous age limit was 12 years.
crossing_the_rubicon
16/3/2020
17:11
#20918 Erm. The soldiers travelled HOME, to a population that on the whole didn't travel and were more rural.
prambigear
16/3/2020
16:55
Zai Lab Ltd. said the China National Medical Products Administration accepted its supplemental new drug application for Zejula as a maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company said the Prima study, conducted by partner GlaxoSmithKline PLC, demonstrated Zejula treatment resulted in a 38% reduction in the risk of disease progression or death in the overall study population when compared to placebo. Zejula demonstrated benefits in all patient subgroups, the company said. For patients whose cancer is associated with homologous recombination deficiency positive status, Zejula treatment resulted in a 57% reduction in the risk of disease progression or death, Zai Lab said. GSK submitted a sNDA to the U.S. Food and Drug Administration for the use of Zejula in ovarian cancer as first-line maintenance treatment and the application was accepted in February.
tradermichael
16/3/2020
13:36
Some people think they know it all but know very little eh PORSCHE Porsche1945 12 Mar '20 - 10:08 - 20885 of 20920 Back in at 1447 to start building a position, I love this share, one of the best for trading I have ever owned, will be serious money to be made on the bounce, the whole thing over hyped and juiced by social media, will soon get boring and markets in general and Gsk in particular will bounce. Its times like this you make real money, as long as you have the funds or Lombard margin.
bc4
16/3/2020
13:03
This isnt Spanish flu or anything like it, virologists say it actually has a kill rate of 0.7 pc, less than normal flu. Completely overhyped, looking forward to buying more of what I like ever cheaper for a nice profit on the bounce.
porsche1945
16/3/2020
11:32
@Abdulla. Indeed, see Cineworld! See Mars. See TLW/PMO See Shell. Simply wow,wow, gobsmacked.
crossing_the_rubicon
16/3/2020
11:31
Erm, it did, in fact, spread very widely. People did travel (millions of troops worldwide) and this facilitated the spread. The Spanish flu infected 500 million people around the world, or about 27% of the then world population of between 1.8 and 1.9 billion, including people on isolated Pacific islands and in the Arctic. Also, you state that it 'came back' at least twice. But this wasn't due to lack of herd immunity, its because it mutated: The second wave of the 1918 pandemic was much deadlier than the first. The first wave had resembled typical flu epidemics; those most at risk were the sick and elderly, while younger, healthier people recovered easily. By August, when the second wave began in France, Sierra Leone, and the United States, the virus had mutated to a much deadlier form. October 1918 was the deadliest month of the whole pandemic.
tradermichael
16/3/2020
11:14
#20911 Correct, and a good example for the government's advisors. People didn't travel then on the whole. Therefore it didn't spread very widely. So no 'herd immunity', it came back, at least twice.
prambigear
Chat Pages: Latest  845  844  843  842  841  840  839  838  837  836  835  834  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200528 19:15:30